Analysts Set Ascendis Pharma A/S (ASND) PT at $51.83

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned an average rating of “Buy” from the eleven brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $51.83.

Several analysts have issued reports on ASND shares. Bank of America lowered their price objective on shares of Ascendis Pharma A/S from $46.00 to $43.00 and set a “buy” rating for the company in a research report on Friday, November 17th. HC Wainwright reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, December 13th. BidaskClub raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. JPMorgan Chase & Co. set a $50.00 price objective on shares of Ascendis Pharma A/S and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Finally, Zacks Investment Research downgraded shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th.

Shares of Ascendis Pharma A/S (ASND) traded up $4.63 during trading hours on Friday, reaching $56.00. 358,600 shares of the company’s stock traded hands, compared to its average volume of 168,102. Ascendis Pharma A/S has a one year low of $21.95 and a one year high of $56.99. The firm has a market capitalization of $1,868.12, a P/E ratio of -15.38 and a beta of 1.02.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, November 16th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.37). Ascendis Pharma A/S had a negative net margin of 4,687.42% and a negative return on equity of 64.10%. equities analysts predict that Ascendis Pharma A/S will post -3.88 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at approximately $7,163,000. California Public Employees Retirement System purchased a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at approximately $430,000. Jane Street Group LLC purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at approximately $352,000. Janus Henderson Group PLC purchased a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at approximately $15,403,000. Finally, Iguana Healthcare Management LLC purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at approximately $1,088,000. Institutional investors own 79.07% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Analysts Set Ascendis Pharma A/S (ASND) PT at $51.83” was originally reported by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://weekherald.com/2018/02/15/analysts-set-ascendis-pharma-a-s-asnd-pt-at-51-83.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply